Triphase gets Health Canada nod to begin Phase I trial of marizomib to treat glioma

Drug development firm Triphase Accelerator has received approval from Health Canada to begin its Phase I trial of marizomib in combination with bevacizumab (Avastin) to treat patients with recurrent malignant glioma in Canada.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news